Uhlén Staffan, Schiöth Helgi B, Jahnsen Jan Anker
Section of Pharmacology/Center for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway; Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden.
Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden.
Eur J Pharmacol. 2016 Oct 5;788:113-121. doi: 10.1016/j.ejphar.2016.06.021. Epub 2016 Jun 16.
Kinetic on and off rate constants for many receptor ligands are difficult to determine with regular radioligand binding technique since only few of the ligands are available in labeled form. Here we developed a new and simple radioligand binding method for determining the kinetic off-rate constant for unlabeled ligands, using whole cells expressing α2A- and α2C-adrenoceptors. The new method involves pre-incubation with unlabeled ligand, centrifugation of microtiter plates in order to adhere the cells to the bottom surface, and then upside-down centrifugation of the plates for few seconds to wash away the non-bound fraction of the pre-incubated ligand. The final on-reaction assay for the radioligand is then started by quick addition of a relatively fast-associating radioligand to the cells. The curve obtained is defined by a fairly simple mathematical formula that reflects the simultaneous dissociation of pre-incubated ligand and association of the radioligand. The method proved to produce highly reproducible results in determining the koff constants for various unlabeled ligands. The results show that the α2C-selectivity of MK912 depends mainly on a very slow off-rate at the α2C-adrenoceptor subtype. Regarding the markedly α2C- over α2A-selective compound spiroxatrine, its much faster on-rate at α2C- than α2A-adrenoceptors explains much of its exceptional α2C-selectivity. Several new techniques for determining the kinetic component of ligand-receptor interactions at molecular level are currently developing. As a reference, based on standard radioligand binding techniques, the present study describes a simple and robust experimental and mathematical procedure for determining koff constants of unlabeled drugs.
由于只有少数配体有标记形式,因此用常规放射性配体结合技术很难测定许多受体配体的动力学结合和解离速率常数。在此,我们开发了一种新的、简单的放射性配体结合方法,用于测定未标记配体的动力学解离速率常数,该方法使用表达α2A -和α2C -肾上腺素能受体的全细胞。新方法包括与未标记配体预孵育,将微量滴定板离心以使细胞粘附到底面,然后将板倒置离心几秒钟以洗去预孵育配体的未结合部分。然后通过向细胞中快速加入一种结合相对较快的放射性配体来开始对放射性配体的最终反应测定。得到的曲线由一个相当简单的数学公式定义,该公式反映了预孵育配体的同时解离和放射性配体的结合。该方法在测定各种未标记配体的解离速率常数时被证明能产生高度可重复的结果。结果表明,MK912的α2C选择性主要取决于其在α2C -肾上腺素能受体亚型上非常缓慢的解离速率。关于明显α2C选择性高于α2A选择性的化合物螺沙群,其在α2C -肾上腺素能受体上比在α2A -肾上腺素能受体上快得多的结合速率解释了其特殊的α2C选择性的很大一部分原因。目前正在开发几种在分子水平上测定配体 - 受体相互作用动力学成分的新技术。作为参考,基于标准放射性配体结合技术,本研究描述了一种简单而稳健地测定未标记药物解离速率常数的实验和数学程序。